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Abstract 
Attention deficit/ hyperactivity disorder (ADHD) is a heritable neurodevelopmental 
disorder featuring complex genetics with common and rare variants contributing to disease 
risk. In a high proportion of cases, ADHD does not remit during adolescence but persists into 
adulthood. Several studies suggest that NOS1, encoding nitric oxide synthase I, producing 
the gaseous neurotransmitter NO, is a candidate gene for (adult) ADHD. We here extended 
our analysis by increasing the original sample, adding two further samples from Norway and 
Spain, and conducted subgroup and co-morbidity analysis. Our previous finding held true in 
the extended sample, and also meta-analysis demonstrated an association of NOS1 ex1f-
VNTR short alleles with adult ADHD (aADHD). Association was restricted to females, as was 
the case in the discovery sample. Subgroup analysis on the single allele level suggested that 
the 21-repeat allele caused the association. Regarding subgroups, we found that NOS1 was 
associated with the hyperactive/impulsive ADHD subtype, but not to pure inattention. In 
terms of comorbidity, major depression, anxiety disorders, cluster C personality disorders 
and migraine were associated with short repeats, in particular the 21-repeat allele. Also, 
short allele carriers had significantly lower IQ. Finally, we again demonstrated an influence of 
the repeat on gene expression in human post-mortem brain samples. These data validate 
the role of NOS-I in hyperactive/impulsive phenotypes and call for further studies into the 
neurobiological underpinnings of this association. 
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Introduction 
 Attention deficit / hyperactivity disorder (ADHD) is the most common 
neurodevelopmental disorder, with an estimated prevalence of around 5%. While a 
proportion of cases remits, a significant part of the patients do not fully recover and feature 
full or partial persistence of the disorder into adulthood, then termed adult ADHD (aADHD) 
(Faraone and others 2006). The childhood manifestation of the disorder is highly heritable – 
around 80% (Faraone and Khan 2006; Franke and others 2012) - and so is aADHD, when 
clinical diagnostic instruments are used (Larsson and others 2013). However, despite 
considerable efforts e.g. in consortia such as the Psychiatric Genomics Consortium, only few 
risk genes have been yet discovered and confirmed. This likely is due to the complex genetic 
architecture of ADHD involving common as well as rare variants, be it in the form of base 
pair mutations or copy number variants. This is even more true for the adult form of ADHD, 
where there are considerably less studies on risk genes (Franke and others 2012). Looking 
across the lifespan, it can be hypothesized that, in addition to genes predisposing to ADHD 
onset as such, genetic variance impacts on the persistence of the disorder (Chang and others 
2013) – in fact, there is already one example where one allele of a polymorphism is 
associated with childhood ADHD, while the other allele is associated with adult ADHD (the 
gene encoding the dopamine transporter DAT (Franke and others 2010)). Finally, it is known 
that aADHD goes along with a high rate of both psychiatric (Jacob and others 2014a; Jacob 
and others 2014b; Jacob and others 2007) as well as somatic (Haavik and others 2010) 
comorbidities. Many of those comorbid phenomena have a heritable basis as well (e.g., (Lee 
and others 2013)), but only few risk variants for such comorbidity have been identified (e.g., 
(Cross-Disorder Group of the Psychiatric Genomics Consortium 2013)).  
 We have previously identified a highly polymorphic repeat in the promoter region of 
the gene encoding nitric oxide synthase 1 (NOS1), termed NOS1 ex1f-VNTR, short alleles of 
which results in lower gene expression in vitro; supposedly such reduced expression is also 
present in the basal ganglia, as the specific splice form is predominantly expressed in this 
part of the brain (Freudenberg 2015; Reif and others 2006; Reif and others 2009; Rife and 
others 2009). The gene product, NOS-I, is the sole source for the gaseous neurotransmitter 
NO in the brain, which is also the second messenger of the NMDA receptor, and which is 
involved in learning, memory, behavioral control and emotional behaviors (Snyder and 
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others 1998). Mice that lack fully functional Nos-I are more aggressive, impulsive, less 
anxious and cognitively impaired (Nelson and others 2006; Wultsch and others 2007). These 
data make NOS1 an excellent candidate gene for ADHD and associated impulsive behaviors. 
Although we could not establish a role for NOS1 ex1f-VNTR in childhood ADHD (potentially 
because of sample size limitations), we have earlier demonstrated that short (i.e, low-
expression) variants of the NOS1 repeat polymorphism are associated with aADHD as well as 
a wide range of impulsive behaviors including aggression, suicidality, and cluster B 
personality disorder (Reif and others 2009). The association with impulsive personality 
domains was sex-specific and found in females only: re-analysis of the case-control data 
reported in Reif and others (2009) revealed no significant association in males, but 
association of short alleles with aADHD in the females (OR=1.26, p=0.04; genotypic p-value 
assuming a recessive effect = 0.009).  
We later replicated the association with impulsive traits in Estonian samples (Laas 
and others 2010), and also observed a gene × environment interaction (Reif and others 
2011a). Also, emotional behaviors were found to be influenced by this polymorphism 
(Kurrikoff and others 2012). Further substantiating an association of NOS1 with behavioral 
traits, brain activation during working memory (Kopf and others 2011) and impulsivity (Kopf 
and others 2012) tasks was shown to be altered by the presence of the short NOS1 alleles. 
Unfortunately, the ex1f-VNTR is not tagged by single nucleotide polymorphisms (SNPs) in 
genome-wide association studies (GWAS), and no hypothesis-free approaches have yet 
confirmed the association with ADHD (although a SNP was found suggestively associated 
with quantitative ADHD symptoms in an early ADHD GWAS (Franke and others 2009)). 
 We here extended the original discovery aADHD sample from 383 to 987 patients, 
and added two additional samples from the IMpACT study group 
(www.impactadultadhdgenomics.org) for meta-analysis. In order to further characterize the 
polymorphism-related phenotype, we subsequently tested for an association with 
quantitative ADHD measures as well as comorbid conditions, based on the known pleiotropy 
of NO action. We also ran an exploratory analysis to see whether an individual short allele is 
associated with the traits in question. Finally, we tested whether the polymorphism indeed 
affects NOS1 expression in vivo in human post-mortem brain specimens to functionally 
characterize the biological role effect of the ADHD risk factor.  
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Material and Methods 
Genotyped samples  
The discovery case-control sample, previously published in part (Reif and others 
2009), consisted of 987 unrelated in– and outpatients (mean age 34.2 years, SD 10.1; 47% 
female) of self-reported central-European descent from the German chapter of the 
International Multicenter persistent ADHD CollaboraTion (IMpACT), who were referred to 
the Department of Psychiatry, University of Würzburg for diagnostic assessment and 
treatment of aADHD. All patients completed a semi-structured clinical interview according to 
DSM-IV (Diagnostic and Statistical Manual for Mental Disorders (Jacob and others 2007)). 
Inclusion criteria were onset before the age of 7 years, life-long persistence, current 
diagnosis and age of recruitment between 18 and 65 years. Childhood ADHD was 
retrospectively assessed with the DSM-IV symptom list for ADHD (17 items) that was used as 
a structured clinical interview, and additionally using the Wender-Utah Rating Scale (WURS; 
61 items). Personality assessment was done using NEO PI-R (Costa 1992). Patients with a 
lifetime diagnosis of bipolar disorder (BPD), schizophrenia, significant neurologic co-
morbidity, mental retardation, substance-induced disorders (before 
detoxification/withdrawal), or other somatic disorders, suggesting organic psychosis or with 
an intelligence quotient (IQ) below 80 were excluded from analysis. For a more detailed 
sample description, please refer to (Franke and others 2010). Information about clinical 
ADHD presentation, comorbid psychiatric disorders (other than those mentioned above) and 
dimensional traits are documented in Supplementary Table I. A comparison of NOS1 ex1f-
VNTR genotypes between published (Reif and others 2009) and recently recruited aADHD 
samples can be found in Supplementary Table II, this shows that allele frequencies between 
analysis waves do not differ. The control sample consisted of 2,019 unrelated healthy 
participants of Caucasian origin (mean age 27.2 years, SD 8.3; 62% female), all stemming 
from the same catchment area as the patient group. Of those, 385 (mean age 31.7 years, SD 
10.8; 48% female) were anonymous blood donors, not screened for psychiatric disorders but 
free of medication. Further 1,634 healthy volunteers (mean age 26.4 years, SD 7.6; 65% 
female) were recruited and screened for psychiatric disorders. Assuming a 5% prevalence of 
ADHD, 19 individuals among the unscreened controls may be ADHD patients, which may 
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affect the allele frequency of an associated polymorphism. Allele frequencies of the NOS1 
ex1f-VNTR however did not differ between screened and unscreened controls (p>>0.05). 
Two further aADHD samples were obtained from IMpACT (Franke and others 2010; 
Halmoy and others 2010; Johansson and others 2008; Reif and others 2011b). The total 
replication sample included 710 aADHD patients (mean age 30.6 years, SD 11.5; 39% female) 
and 847 controls (mean age 48.7 years, SD 14.5; 45% female) of Norwegian (ncases=416; 
ncontrols=535) and Spanish (ncases=294; ncontrols=312) origin. All patients were evaluated by 
experienced psychiatrists and diagnosed with persistent ADHD according to DSM-IV criteria 
using standardized clinical interviews. Consensus eligibility criteria for this study across all 
study sites were a diagnosis of ADHD according to the diagnostic criteria of DSM-IV, age at 
onset <7 years by retrospective diagnosis (which was confirmed by family members, 
wherever possible), life-long persistence, and current diagnosis. Norwegian controls were 
free of psychotropic medication, but not screened for psychiatric disorders; Spanish healthy 
volunteers were screened for and free of psychiatric disorders. Further information on 
replication samples can be obtained from Supplementary Table I. All patients and volunteers 
provided written informed consent after oral and written explanation about scope and aim 
of the investigation. The studies complied with the Declaration of Helsinki and were 
approved by the local ethical committees of the respective universities.  
Genotyping of NOS1 ex1f-VNTR 
The highly polymorphic ex1f-VNTR repeat, located in the upstream region of NOS1 
(GRCh 38: 117361839bp-117361898bp), consists mainly of 19 to 36 and in rare cases of 8 or 
15 “GT” dinucleotide units. To facilitate genetic association studies, NOS1 ex1f-VNTR alleles 
were dichotomized in short (8, 15 and 19-27 (GT) repeats, “S”) and long (28-36 (GT) repeats, 
“L”) alleles based on the historical median split; prevalent “S” and “L” alleles differ in 
promoter activation (Reif and others 2009) and the split was defined between rare alleles 
(Figure 1). 
Genomic DNA for genotyping was extracted from venous blood of all participants, by 
a standard de-salting method. NOS1 ex1f-VNTR alleles were identified using a polymerase 
chain reaction (PCR) amplification step followed by electrophoretic separation and product 
size determination on a DNA sequencer (CEQ8000; Beckman-Coulter, Krefeld, Germany) as 
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previously described in greater detail (Reif and others 2006). Primers and PCR conditions are 
available on request.  
Statistical Analysis of NOS1 ex1f-VNTR 
Statistical analysis of genotype data was performed with R version 2.15.2 (obtained 
from www.R-project.org). Genotypes of all three case and control samples did not deviate 
from Hardy-Weinberg equilibrium (HWE; χ
2
 HWE p-value ≥ 0.05). To alleviate the possible 
effect of ethnic discrepancies, calculations were performed in each sample separately; for 
joint analyses, samples were subjected to meta-analysis (see below). The primary analysis 
carried out was a case-control comparison with allele counts (S vs. L). For better comparison 
with the results of Reif and others 2009 in second S allele homozygote counts (S/S vs. 
S/L+L/L, “recessive model”) were analyzed post-hoc. Further post-hoc analyses were 
calculated for “21-repeat” allele counts (“21” vs. rest). These tests used 1-degree-of-
freedom χ
2
- tests. In case of fewer than five occurrences per cell of the contingency table 
Fisher’s exact tests were used. We focused on the 21-repeat allele as it represents the only 
common (MAF > 5%) repeat length with significantly different frequencies between affected 
and unaffected individuals (see Supplementary Table III). Effect sizes were quantified with 
Cramer's phi. 
 Impact of genotypes on IQ and WURS sum scores were determined post-hoc with 
linear regression (R function lm) using genotype dosages (additive model) as independent 
and the trait of interest as dependent variable; both scores were also analyzed with a 
recessive model (SS vs. SL+LL) using grouped genotypes. ANOVA was used to examine 
interaction between genotype and sex effects (R function anova.lm). Effect size was 
quantified by Cohen´s f. P-values<0.05 indicated statistical significance. 
Meta-analysis 
To obtain maximal information regarding the NOS1 ex1f-VNTR, we conducted a 
meta-analysis of the German, Norwegian and Spanish samples and thereby achieve a pooled 
sample power of 70% assuming a co-dominant model, a MAF of 0.05 (Power for Genetic 
Association version 2.0) and a relative risk of 1.25 to develop aADHD. 
Meta-analyses were performed with the R package metaphor version 0.5-7 
(Viechtbauer 2009) using the “rma” command. As a measure for effect size, we calculated 
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odds ratios (ORs) and applied the Q-statistic (Fleiss 1981; Lau and others 1997) to assess 
heterogeneity therein. Inconsistency across studies was quantified with the I^2 metric 
(I^2=(Q-df)/Q). The joint OR was determined as the weighted average of effect sizes entering 
the meta-analysis. When the Q-statistic showed no heterogeneity in the effect sizes, we 
applied fixed-effects models (Mantel and Haenszel 1959), where the weights correspond to 
the inversed variances of the study ORs. In the presence of significant (p<0.05) 
heterogeneity, we applied random-effects models (DerSimonian and Laird 1986). Here, 
weights are initially calculated as in the fixed-effects model, but are then down-weighted by 
the degree of variance of effect sizes.  
Influence of NOS1 ex1f-VNTR on mRNA expression 
 The influence of NOS1 ex1f-VNTR on mRNA expression was examined in 
human post-mortem brain (post-mortem intervals (PMI) from 28 h up to 111 h; mean PMI 
54.8 h; SD 16.6) of 76 deceased individuals (mean age 48.6 years, SD 12.8; 24% female), all 
obtained from the Medical Research Council (MRC) Sudden Death Brain and Tissue Bank, 
Edinburgh. DNA and RNA from three brain regions (amygdala, forebrain, and midbrain) were 
isolated, using the MELT
TM
 Total Nucleic Acid Isolation System (Applied Biosystem, AM 
Foster City, 1983) and stored at -80°C until use. RNA quality, measured with a Bioanalyzer 
(Agilent), revealed RNA integrity numbers (RIN) ranging from 2.4 to 8.1 (mean RIN 5.9; SD 
0.94). Reverse transcription of 1 µg total RNA was done by using the iScript™ cDNA synthesis 
kit (Bio-Rad, München, Germany). cDNA was quantified in triplicates on a Bio-Rad CFX384 
real-time PCR detection system, by applying the iQ™ SYBR green supermix from Bio-Rad and 
NOS1-specific QuantiTect Primer (QT00043372) from Qiagen in a 10 µl reaction volume. PCR 
conditions were 5 min at 95°C, 40 cycles of 10 s at 95°C, 30 s at 60°C, followed by a melting 
curve analysis with a gradient of 65°C to 95°C of 0.5°C per 5 s. Raw data were normalized by 
mean efficiencies obtained from LinRegPCR (Ramakers and others 2003) and normalization 
factors based on the three (of six investigated) most stable housekeeping genes (GAPDH, 
TBP, SDHA), defined by the geNorm (Vandesompele and others 2002) software. The 
influence of NOS1 ex1f-VNTR on mRNA expression was quantified with linear regression 
using additive and recessive (SS vs. SL+LL) genotype models with genotype and the sample 
RIN as independent and expression values as dependent (co-) variable.  Effect sizes were 
quantified by Cohen´s f. 
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Results 
Association analysis of NOS1 ex1f-VNTR in three independent aADHD case-control samples 
Due to different geographic origin of our study samples, allelic and recessive model 
associations were first determined separately in each sample; a meta-analysis was then 
conducted to assess the statistical significance of the pooled effect sizes with maximal 
statistical power (Table I and Figure 2, Supplementary Figure 1). When all three samples 
were analyzed jointly using a meta-analytic approach with a sample size totaling to 1,697 
cases and 2,866 controls, short alleles were significantly associated with aADHD, however 
only when the analysis was restricted to females (PFixed=0.049; OR=1.14 [95% CI: 1.00-1.29]; 
Figure 2B) as it was the case in the discovery sample. 
To test which of the 19 NOS1 ex1f-VNTR alleles conveys the genetic predisposition 
towards aADHD, additional allelic case-control analyses were conducted for each of the 19 
repeats, versus all other repeats (Supplementary Table III). In doing so, we found that the 
21-repeat allele significantly increases the risk for aADHD in German females (p=0.023; 
Cramer's phi=0.039). Subsequent meta-analysis did however not confirm the genetic risk 
status of the 21-repeat allele both in the total sample (PFixed=0.116; OR=1.19 [95% CI: 0.96-
1.46) as well as in its female subset (PRandom=0.620; OR=0.81 [95% CI: 0.34-1.90]; see 
Supplementary Table IV). 
Association analysis of NOS1 ex1f-VNTR with aADHD clinical presentations 
To examine whether NOS1 ex1f-VNTR is specifically linked to one of the ADHD sub-
phenotypes (inattentive (AD), hyperactive/impulsive (HD), or combined (AD+HD) 
presentation), we performed allelic and recessive model association analyses with all three 
ADHD clinical presentations by meta-analysis (Table II, Supplementary Table V, 
Supplementary Figures 2, 3, 4 and 5). In the allelic meta-analysis, short repeats were found 
to predispose to the hyperactive/impulsive (HD)  (PFixed=0.032;  OR=1.67 [95% CI: 1.07-2.62]) 
and the combined subtype (AD+HD)  (PFixed=0.026; OR=1.18 [95% CI: 1.02-1.36]) in females. 
In line with these findings, allelic case-control associations investigating the 21-repeat 
allele again revealed an increased risk for the AD+HD subtype in German females (p=0.030; 
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Cramer's phi=0.039) and Spanish males (p=0.010; Cramer's phi=0.095), as well as in the HD 
subtype in the Norwegian sample (p=0.001; Cramer's phi=0.143). However, meta-analytic 
treatment did not result in a significant association (see Supplementary Table VI). 
Association analysis of NOS1 ex1f-VNTR with comorbid disorders 
 In an exploratory manner, we assessed the impact of NOS1 ex1f-VNTR on comorbid 
disorders, specifically Substance Abuse (Alcohol: SUDAlc and Drugs: SUDDrug), Major 
Depression (MD), Anxiety Disorder (AnxDis), Personality Disorders Cluster A (CL_A), B (CL_B) 
and C (CL_C), and Migraine (Migr), in the German, Norwegian and Spanish samples (see 
Tables III and IV and Supplementary Tables VII and VIII). In the allelic model, meta-analyses 
of all examined phenotypes revealed an association of NOS1 ex1f-VNTR with comorbid MD, 
AnxDis and Migr, in all cases with the short allele being the risk factor. While AnxDis were 
associated with NOS1 in the total sample (PFixed=0.024; OR=1.17 [95% CI: 1.02-1.34]), we 
observed a sex bias for MD (Total: PFixed=0.006; OR=1.18 [95% CI: 1.05-1.33]; males: 
PFixed=0.045; OR=1.19 [95% CI: 1.01-1.41]) and Migr (Total: PFixed=0.007; OR=1.27 [95% CI: 
1.07-1.50]; females: PFixed=0.022; OR=1.31 [95% CI: 1.05-1.64]). Likewise, we also observed 
an association with Cl_C in males using the recessive model meta-analysis (PFixed=0.050; 
OR=2.72 [95% CI: 1.14-6.51]; See Supplementary Table VIII). 
Single allele meta-analysis of comorbid MD with the 21-repeat (Total: PFixed=0.019; 
OR=1.38 [95% CI: 0.95-1.97]); males: PFixed=0.015; OR=1.61 [95% CI: 1.112.34]) reflected the 
association results of the S allele, which points to the 21-repeat allele being the main driver 
for the genetic risk of the S allele. Also in comorbid Migr, the 21-repeat allele was 
significantly associated with the co-morbid disorder, caused mainly by association in males 
(Migr: PFixed=0.039; OR=1.84 [95% CI: 1.07-3.16]; See Supplementary Table IX). 
In the following exploratory analysis, we examined the impact of NOS1 ex1f-VNTR on 
WURS and IQ in the German sample. The S allele has no significant effect on the WURS sum 
score (p>0.05). Also, no association with IQ scores was found with the allelic model. Grouped 
genotypes (SS: 109.2 ± 12.6 vs. SL+LL: 111.7 ± 14.1) revealed however a significantly 
decreased IQ score (betaTotal=-2.57; betaFemale=-3.77) for homozygous S-allele carriers in the 
total sample (precessive=0.040; Cohen´s effect-size (f
2
)=0.007) and in females (precessive=0.030; 
Cohen´s f
2
=0.015).  
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Functional effect of NOS1 ex1f-VNTR on gene expression 
Quantification of mRNA in human post-mortem amygdalae revealed a significant 
increase of total NOS1 expression values (Total: betaallelic=0.47; betarecessive=0.73; Male: 
betaallelic=0.55; betarecessive=0.93) for the short risk allele of NOS1 ex1f-VNTR in the total MRC 
sample (N=59; pallelic=0.030; Cohen´s effect-size (f
2
)=0.108; precessive=0.040; Cohen´s f
2
=0.097) 
and the male (N=45; pallelic=0.039; Cohen´s f
2
=0.132; precessive=0.036; Cohen´s f
2
=0.135), but 
not the female subset (N=14; pallelic=0.531; precessive=0.733). Neither in forebrain (N=64; 
pbest=0.196) nor in midbrain (N=55; pbest=0.329) NOS1 ex1f-VNTR affected mRNA expression 
(Supplementary Figure 6). Unfortunately, no other brain regions were available for further 
analysis. 
 
Discussion 
The present study aimed to corroborate the association of NOS1 ex1f-VNTR with 
aADHD (Reif and others 2009) and related phenotypes (Freudenberg 2015). The association 
with aADHD in the original study was specific to females, but no attempt at replication has 
been published to date. We almost tripled the size of the original discovery sample (Reif and 
others 2009) and furthermore added two independent samples for meta-analysis. Overall, 
our data confirmed a sex-specific association of NOS1 ex1f-VNTR with aADHD, especially 
with clinical presentations featuring hyperactive/impulsive symptoms and also with 
comorbid AnxDis, MD, CL_C and Migr.  
In reporter gene assays, short repeat lengths consistently resulted in lower gene 
expression as shown by two independent groups (Reif and others 2009; Rife and others 
2009). In contrast, we here detected increased NOS1 expression in the amygdala in short 
allele carriers. However, despite it is well known that NOS1 is expressed in the amygdala, it is 
unclear which alternative first exon (and hence alternative promoter) drives expression in 
this structure. As the effect of the NOS1 ex1f-VNTR genotype may be highly tissue-specific, 
and also as we measured total NOS1 driven from alternative promoters, our data might 
represent compensatory up-regulation of total NOS1 in response to decreased NOS1 ex1f 
expression either in the amygdala as such or elsewhere. Also, since both cell lines used for 
the reporter gene assays (HeLa and Sk-n-Mc (Reif and others 2009; Rife and others 2009)) 
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were originally derived from cancer tissue of female donors, whereas the post-mortem brain 
sample was mainly composed of male specimens (76%), one may speculate that the 
observed discordance of S allele effects reflects the sex differences found in the association 
studies (see below). Further studies in larger samples of human tissue are clearly warranted 
to clarify the molecular effect of the NOS1 ex1f-VNTR. 
Association of NOS1 with adult ADHD 
Our initial finding (Reif and others 2009), namely that short NOS1 ex1f-VNTR alleles 
are associated with aADHD in females, was successfully replicated in the German sample. A 
validation using Spanish and Norwegian samples did however not succeed; differences in the 
genetic background due to the ethnic composition of the samples as well as sample size 
constraints (sample sizes were not even half as large as the German sample) provide 
plausible explanations for the failure to replicate. Meta-analysis of NOS1 ex1f-VNTR of three 
samples however confirmed the sex-specific association; since sex distribution in samples 
was almost balanced, power considerations may rather not explain the observed differences 
between males and females. Hence, biological mechanisms might form an alternative 
explanation, and in this context it is noteworthy that a cis-acting estrogen binding site is 
present directly upstream of the NOS1 ex1f-VNTR, so that effects of sex hormones on NOS1 
expression seem plausible. Sex-specific associations with NOS1 ex1f-VNTR were previously 
observed in an independent sample representing the general population (Kurrikoff and 
others 2012). Moreover, in murine models for aggression, effects of Nos1 deficiency were 
shown in both sexes, however in the opposing direction: male mice became more 
(Chiavegatto and others 2001) and female mice became less aggressive (Gammie and Nelson 
1999). The latter observation was confirmed by a selective breeding approach, where mice 
selected for high maternal aggression were found to have increased Nos1 expression 
(Gammie and others 2007). Sex effects thus should be explicitly addressed in further studies 
on NOS1’s role in behavior and psychopathology.  
Despite considerable sample size, our data is not definitive as the strength of 
association is not very pronounced; also, the effect in the German sample was the most 
significant, suggesting that the association of NOS1 with aADHD follows the “winner’s 
curse”. However, the finding that short alleles convey risk across all published studies 
(Freudenberg 2015) and also in the present dataset supports the hypothesis that psychiatric 
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disorders are influenced by NOS1 ex1f-VNTR and hence NOS1 might constitute one example 
of risk genes that underlie the frequently observed comorbidity of psychiatric disorders. The 
NOS1 ex1f-VNTR effect on examined phenotypes was generally modest as it usually is in 
polygenic traits (Freudenberg 2015). Also, the rather crude distinction in short and long 
alleles (originally merely based on statistical reasons, i.e. the median repeat length) might 
obscure biological effects. A more detailed analysis of all individual alleles suggested the 21-
repeats to be associated with the phenotypes in question, at least in the German sample. 
Although here, respective calculations yielded stronger significance levels and thus greater 
effect sizes as compared to the short/long dichotomized polymorphism, discordant results 
were obtained from the Norwegian and Spanish samples, thus demanding further and larger 
samples to detail if the genetic risk is indeed conveyed by the 21-repeat allele.  
aADHD subtype and comorbid disorders  
As the IMpACT samples are well characterized and broadly phenotyped, this provided 
the opportunity to run exploratory analyses on dimensional traits and co-morbid conditions 
(although these findings have to be considered with caution until replicated). A plethora of 
pharmacological and genetic studies in rodents suggest a role of NOS-I in anxiety and mood 
regulation (Gao and others 2014; Gao and others 2013; Gregers 2011; Pereira and others 
2013; Yazir and others 2012). Accordingly, there is (more scarce) evidence that mood 
disorders are influenced by NOS1: a SNP in exon 29, for example, increased the risk for 
recurrent depressive disorder in a preliminary study (Galecki and others 2011), and the 
NOS1 ex1f-VNTR S allele went along with significantly higher depressiveness in a population-
representative sample (Kurrikoff and others 2012). To our best knowledge, there are no 
other studies on NOS1 ex1f-VNTR and depression or anxiety in humans despite the wealth of 
preclinical non-genetic human data suggesting an involvement of NOS-I in depression and 
anxiety. In the context of aADHD, as tested in the present study, both affective and anxiety 
disorders seem to be linked to short alleles of NOS1 ex1f-VNTR indicating that NOS1 may 
also have a role in emotional behaviors in humans. Regarding substance use disorders, a role 
for NOS1 could especially be assumed given data from knockout mice (Spanagel and others 
2002); however, no effect could be found in our human sample. This of course does not rule 
out a role for NOS-I in alcohol abuse, but argue against a major contribution through a 
common genetic variant in the gene. Also, we could not replicate our previous finding (Reif 
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and others 2009) that short NOS1 alleles are associated with Cluster B personality disorders, 
although a trend towards an association was seen in the recessive model (corresponding to 
the analysis strategy of the original discovery) meta-analysis of the total sample. The reason 
for this likely is sample size (only 126 patients were included here, in contrast to 322 patients 
in the initial study).  
Previously we have presented evidence for comorbidity between ADHD and migraine 
(Fasmer and others 2011). The association between NOS1 and migraine in ADHD patients is 
interesting (Table III) with regard to the  abundant data showing the involvement of NO in 
migraine pathophysiology (de O. S. Mansur and others 2012). The present findings therefore 
suggest that NOS1 may be a link between these two disorders.  
The exploratory ADHD subtype analysis might guide follow-up studies. In line with 
our prior hypothesis that NOS-I has a role especially in hyperactivity and motor impulsivity 
(Reif and others 2009), we here demonstrate preliminary evidence that short alleles are 
associated with hyperactive/impulsive subtypes of ADHD, but not pure inattentive adult 
ADHD. The neurobiological rationale for this might be that NOS-I modulates striatal function 
by its influence on dopaminergic neurotransmission. Thus, it seems to be especially 
worthwhile to test NOS1 ex1f-VNTR’s influence on impulsive phenotypes mediated by the 
striatum and whether this interacts with the dopamine system. Finally, we here also found a 
negative effect of the short allele on general IQ. Keeping in mind previously found influences 
of NOS1 on verbal IQ (Donohoe and others 2009), one may hypothesize a specific role of 
NOS-I in verbal intelligence which is currently under investigation in our laboratory along 
with neuroimaging experiments in order to identify the neural correlates thereof. 
Taken together, the present study strengthens the notion that short alleles – 
potentially the 21-repeat allele – of NOS1 ex1f-VNTR are associated with aADHD in a sex 
specific manner; its role likely is complex with effects on hyperactivity/impulsivity, stress-
related disorders, migraine and IQ. NOS-I thus might be a molecular link between these 
phenotypes, explaining at least a little genetic part of the observed co-morbidity of ADHD 
with these phenotypes. This hypothesis could be directly tested in further studies, and also, 
functional studies are warranted to elucidate the neurobiological pathways that link genetic 
variation to neural systems and behavior.  
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Figures (2)  
Figure 1: Chromosomal position of the NOS1 ex1f-VNTR according to NCBI´s genome built GRCh 38 
and distribution of the repeat length variants in German, Norwegian and Spanish samples. 
 
Figure 2: Forest plots of NOS1 ex1f-VNTR recessive and allelic model in the total sample (A), as well 
as the female (B) and the male (C) subset.  
 
Tables (4) 
Table I:  Association results for the NOS1 ex1f-VNTR in the German, Norwegian and Spanish 
samples, followed by meta-analysis. Table shows allele and genotype counts for cases and controls, 
as well as χ2- and the p-value of the calculated allelic (S-alleles vs. L-alleles) and recessive (SS vs. 
SL+LL) and models in the total sample, and their sex-specific subsets. Further, total cases and control 
counts are given for the allelic and recessive models as well as p-values for heterogeneity and odds 
ratios plus p-values of the fixed effect model. Bold face indicates significant p-values (p<0.05). 
 
Table II:  Association results of aADHD clinical presentations (inattentive (AD), hyperactive (HD), and 
combined (AD+HD) type ADHD) for the NOS1 ex1f-VNTR in the German, Norwegian and Spanish 
sample, followed by a meta-analysis. Along allele counts for cases and controls, the χ2- and the p-
value of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender 
specific subsets are shown. Further, total cases and control counts, p-values for heterogeneity and 
odds ratios plus p-values of the fixed effect model are given. Bold face indicates significant p-values 
(p<0.05). 
 
Table III: Association results of NOS1 ex1f-VNTR with comorbid axis 1 disorders (Substance Abuse 
(Alcohol: SUDAlc and Illicit Drugs: SUDDrug), Major Depression (MD), Anxiety Disorder (AnxDis)) in 
the German, Norwegian and Spanish samples, followed by meta-analysis. Along allele and genotype 
counts for cases and controls, the χ2- and the p-value of the calculated allelic (S-alleles vs. L-alleles) 
model in the total sample, as well as their gender specific subsets are shown. Further, total cases and 
control allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model 
are given. Bold face indicates significant p-values (p<0.05). 
 
Table IV: Association results of NOS1 ex1f-VNTR with comorbid co-morbid axis 2 and somatic 
disorders (Personality Disorder Cluster A (CL_A), B (CL_B) and C (CL_C), Migraine (Migr)) in the 
German, Norwegian and Spanish sample, followed meta-analysis. Along allele and genotype counts 
for cases and controls, the χ2- and the p-value of the calculated allelic (S-alleles vs. L-alleles) model in 
the total sample, as well as their gender specific subsets are shown. Further, total cases and control 
allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model are 
given. Bold face indicates significant p-values (p<0.05). 
 
Supplementary Figures (6) 
 
Supplementary Figure 1: Funnel plots of NOS1 ex1f-VNTR recessive and allelic model in the total 
sample (A), as well as the female (B) and the male (C) subset. 
Supplementary Figure 2: Forest plots of allelic NOS1 VNTR meta-analysis on aADHD clinical 
presentations (A) inattentive (AD), (B) hyperactive (HD), and (C) combined (AD+HD) type in the total 
sample and its sex specific subsets.  
 
Supplementary Figure 3: Funnel plots of allelic NOS1 VNTR meta-analysis on aADHD clinical 
presentations (A) inattentive (AD), (B) hyperactive (HD), and (C) combined (AD+HD) type in the total 
sample and its sex specific subsets.  
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Supplementary Figure 4: Forest plots of recessive NOS1 VNTR meta-analysis on aADHD clinical 
presentations (A) inattentive (AD), (B) hyperactive (HD), and (C) combined (AD+HD) type in the total 
sample and its sex specific subsets. 
 
Supplementary Figure 5: Funnel plots of recessive NOS1 VNTR meta-analysis on aADHD clinical 
presentations (A) inattentive (AD), (B) hyperactive (HD), and (C) combined (AD+HD) type in the total 
sample and its sex specific subsets.  
 
Supplementary Figure 6: Genotype-specific NOS1 ex1f expression in different brain regions. 
 
Supplementary Tables (9) 
 
Supplementary Table I: Demographic overview  
 
Supplementary Table II: Comparison of the NOS1 ex1f-VNTR genotypes between the former (Reif 
and others, 2009) and recent aADHD samples using allelic (S-alleles vs. L-alleles) and recessive (SS 
vs. SL+LL) models. Bold face indicates significant p-values (p<0.05). 
 
Supplementary Table III:  Distribution of the 19 NOS1 ex1f-VNTR-repeat alleles  
 
Supplementary Table IV: Association results for the 21-repeat allele of NOS1 ex1f-VNTR in the 
German, Norwegian and Spanish samples, followed by meta-analysis. Along allele counts for cases 
and controls, the χ2- and the p-value of the calculated allelic (21-repeat-alleles vs. all other alleles) 
model in the total sample, as well as their gender specific subsets are shown. Further, total cases and 
control counts, p-values for heterogeneity and odds ratios plus p-values of the fixed or random effect 
model are given. Bold face indicates significant p-values (p<0.05). 
Supplementary Table V: Association results of aADHD clinical presentations (inattentive (AD), 
hyperactive (HD), and combined (AD+HD) type ADHD) for the NOS1 ex1f-VNTR in the German, 
Norwegian and Spanish sample. Along allele counts for cases and controls, the χ2- and the p-value of 
the calculated recessive (SS vs. SL+LL) model in the total sample, as well as their gender specific 
subsets are shown. Further, total cases and control counts, p-values for heterogeneity and odds ratios 
plus p-values of the fixed effect model are given. Bold face indicates significant p-values (p<0.05). 
Supplementary Table VI: Association results of the three aADHD clinical presentations (inattentive 
(AD), hyperactive (HD), combined (AD+HD)) for the 21-repeat all le of the NOS1 ex1f-VNTR in the 
German, Norwegian and Spanish sample, followed by a meta-analysis. Along allele counts for cases 
and controls, the χ2- and the p-value of the calculated allelic (21-repeat alleles vs. all other alleles) 
model in the total sample, as well as their gender specific subsets are shown. Further, total cases and 
control counts, p-values for heterogeneity and odds ratios plus p-values of the fixed or random effect 
model are given. Bold face indicates significant p-values (p<0.05). 
 
Supplementary Table VII: Association results of NOS1 ex1f-VNTR with comorbid axis 1 disorders 
(Substance Abuse (Alcohol: SUDAlc and Illicit Drugs: SUDDrug), Major Depression (MD), Anxiety 
Disorder (AnxDis)) in the German, Norwegian and Spanish samples, followed by meta-analysis. Along 
allele and genotype counts for cases and controls, the χ2- and the p-value of the calculated recessive 
(SS vs. SL+LL) model in the total sample, as well as their gender specific subsets are shown. Further, 
total cases and control allele counts, p-values for heterogeneity and odds ratios plus p-values of the 
fixed effect model are given. Bold face indicates significant p-values (p<0.05). 
 
Supplementary Table VIII: Association results of NOS1 ex1f-VNTR with comorbid co-morbid axis 2 
and somatic disorders (Personality Disorder Cluster A (CL_A), B (CL_B) and C (CL_C), Migraine 
(Migr)) in the German, Norwegian and Spanish sample, followed by meta-analysis. Along allele and 
genotype counts for cases and controls, the χ2- and the p-value of the calculated recessive (SS vs. 
SL+LL) model in the total sample, as well as their gender specific subsets are shown. Further, total 
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cases and control allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed 
effect model are given. Bold face indicates significant p-values (p<0.05). 
 
Supplementary Table IX: Association results of the 21-repeat allele of NOS1 ex1f-VNTR with 
comorbid disorders (major depression (MD), anxiety disorders (AnxDis), migraine (Migr) for in the 
German, Norwegian and Spanish sample, followed by meta-analysis. Along allele counts for cases 
and controls, the χ2- and the p-value of the calculated allelic (21-repeat alleles vs. all other alleles) 
model in the total sample, as well as their gender specific subsets are shown. Further, total cases and 
control counts, p-values for heterogeneity and odds ratios plus p-values of the fixed or random effect 
model are given. Bold face indicates significant p-values (p<0.05). 
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Figure 1: Chromosomal position of the NOS1 ex1f-VNTR according to NCBI´s genome built GRCh 38 and 
distribution of the repeat length variants in German, Norwegian and Spanish samples.  
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Figure 2: Forest plots of NOS1 ex1f-VNTR recessive and allelic model in the total sample (A), as well as the 
female (B) and the male (C) subset.  
270x361mm (300 x 300 DPI)  
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Table I:  Association results for the NOS1 ex1f-VNTR in the German, Norwegian and Spanish 
samples, followed by meta-analysis. Table shows allele and genotype counts for cases and controls, 
as well as χ2- and the p-value of the calculated allelic (S-alleles vs. L-alleles) and recessive (SS vs. 
SL+LL) and models in the total sample, and their sex-specific subsets. Further, total cases and control 
counts are given for the allelic and recessive models as well as p-values for heterogeneity and odds 
ratios plus p-values of the fixed effect model. Bold face indicates significant p-values (p<0.05). 
 
  
Total Females Males 
S/L SS/SL+LL S/L SS/SL+LL S/L SS/SL+LL 
German Sample       
Cases 956/1018 233/754 464/454 112/347 492/564 121/407 
Controls 1870/2168 413/1606 1162/1342 253/999 708/826 160/607 
χ2-value 2.39 3.90 4.61 3.52 0.05 0.78 
P-value 0.122 0.048 0.032 0.061 0.827 0.378 
Norwegian Sample    
Cases 422/410 97/319 199/199 41/158 223/211 56/161 
Controls 519/551 119/416 283/309 65/231 236/242 54/185 
χ2-value 0.92 0.15 0.46 0.13 0.37 0.64 
P-value 0.338 0.695 0.498 0.718 0.544 0.423 
Spanish Sample        
Cases 290/298 71/223 76/84 17/63 214/214 54/160 
Controls 312/312 81/231 83/85 20/64 229/227 61/167 
χ2-value 0.06 0.26 0.12 0.15 0.00 0.13 
P-value 0.813 0.607 0.730 0.695 0.948 0.716 
Total: 
  
  
   Cases 1668/1726 401/1296 752/744 175/573 1002/1084 246/797 
Controls 2701/3031 613/2253 1528/1736 338/1294 1173/1295 275/959 
Heterogeneity:     
   Q (df = 2) 0.83 1.93 1.19 2.18 0.25 0.81 
P-value 0.66 0.38 0.552 0.336 0.884 0.668 
Cochran-Mantel-Haenszel Metaanalysis:   
   Fixed effect 1.07 1.12 1.14 1.14 1.03 1.09 
P-value 0.116 0.135 0.049 0.233 0.699 0.418 
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Table II:  Association results of aADHD clinical presentations (inattentive (AD), hyperactive (HD), and 
combined (AD+HD) type ADHD) for the NOS1 ex1f-VNTR in the German, Norwegian and Spanish 
sample, followed by a meta-analysis. Along allele counts for cases and controls, the χ2- and the p-
value of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender 
specific subsets are shown. Further, total cases and control counts, p-values for heterogeneity and 
odds ratios plus p-values of the fixed effect model are given. Bold face indicates significant p-values 
(p<0.05). 
 
  
Total Females Males 
AD HD AD+HD AD HD AD+HD AD HD AD+HD 
German Sample    
 
      
Cases (S/L) 214/244 83/67 659/707 94/90 34/26 336/338 120/154 49/41 323/369 
Controls (S/L) 1870/2168 1870/2168 1870/2168 1162/1342 1162/1342 1162/1342 708/826 708/826 708/826 
χ2-value 0.03 4.73 1.53 1.51 2.48 2.53 0.52 2.35 0.05 
P-value 0.866 0.030 0.216 0.219 0.115 0.112 0.471 0.125 0.819 
Norwegian Sample    
 
   
 
 
Cases (S/L) 65/71 29/27 225/209 27/35 11/5 130/122 38/36 18/22 95/87 
Controls (S/L) 519/551 519/551 519/551 283/309 283/309 283/309 236/242 236/242 236/242 
χ2-value 0.02 0.23 1.38 0.41 2.74 1.01 0.10 0.28 0.42 
P-value 0.876 0.632 0.241 0.523 0.098 0.314 0.751 0.595 0.517 
Spanish Sample    
 
   
 
 
Cases (S/L) 93/89 10/12 187/197 25/29 2/2 49/53 68/60 8/10 138/144 
Controls (S/L) 312/312 312/312 312/312 83/85 83/85 83/85 229/227 229/227 229/227 
χ2-value 0.07 0.18 0.16 0.16 - 0.05 0.34 0.23 0.11 
P-value 0.794 0.675 0.688 0.691 1.000 0.828 0.561 0.631 0.735 
Total: 
  
 
  
 
  
 
Cases (S/L) 372/404 122/106 1071/1113 146/154 47/33 515/513 226/250 75/73 556/600 
Controls (S/L) 2701/3031 2701/3031 2701/3031 1528/1736 1528/1736 1528/1736 1173/1295 1173/1295 1173/1295 
Heterogeneity:    
 
 
  
 
Q (df = 2) 0.09 1.62 1.21 0.97 1.34 1.95 0.94 2.28 0.51 
P-value 0.958 0.445 0.546 0.615 0.511 0.377 0.625 0.318 0.776 
Cochran-Mantel-Haenszel Metaanalysis:   
 
 
  
 
Fixed effect 1.01 1.29 1.07 1.11 1.67 1.18 0.99 1.14 1.02 
P-value 0.884 0.071 0.181 0.442 0.032 0.026 0.935 0.505 0.803 
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Table III: Association results of NOS1 ex1f-VNTR with comorbid axis 1 disorders (Substance Abuse (Alcohol: SUDAlc and Illicit Drugs: SUDDrug), Major 
Depression (MD), Anxiety Disorder (AnxDis)) in the German, Norwegian and Spanish samples, followed by meta-analysis. Along allele and genotype counts for 
cases and controls, the χ2- and the p-value of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender specific subsets are 
shown. Further, total cases and control allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model are given. Bold face 
indicates significant p-values (p<0.05). 
 
  Total Females Males 
  
 
SUDALc SUDDrug MD AnxDis SUDALc SUDDrug MD AnxDis SUDALc SUDDrug MD AnxDis 
German Sample                 
Cases (S/L) 
 
125/127 201/199 370/354 189/181 49/41 82/68 198/188 113/105 76/86 119/131 172/166 76/76 
Controls (S/L) 
 
1870/2168 1870/2168 1870/2168 1870/2168 1162/1342 1162/1342 1162/1342 1162/1342 708/826 708/826 708/826 708/826 
χ2-value 
 
1.03 2.27 5.67 3.10 2.26 3.88 3.21 2.37 0.03 0.18 2.49 0.82 
P-value 
 
0.309 0.132 0.017 0.078 0.133 0.049 0.073 0.123 0.854 0.671 0.115 0.365 
Norwegian Sample                 
Cases (S/L) 
 
91/105 108/110 289/261 289/261 28/34 36/34 141/135 141/135 63/71 72/76 148/126 148/126 
Controls (S/L) 
 
519/551 519/551 519/551 519/551 283/309 283/309 283/309 283/309 236/242 236/242 236/242 236/242 
χ2-value 
 
0.29 0.08 2.37 2.37 0.16 0.33 0.81 0.81 0.23 0.02 1.50 1.50 
P-value 
 
0.593 0.780 0.124 0.124 0.692 0.566 0.368 0.368 0.630 0.878 0.220 0.220 
Spanish Sample                 
Cases (S/L) 
 
57/69 100/110 106/98 91/85 0/8 11/13 37/37 27/33 57/61 89/97 69/61 64/52 
Controls (S/L) 
 
312/312 312/312 312/312 312/312 83/85 83/85 83/85 83/85 229/227 229/227 229/227 229/227 
χ2-value 
 
0.95 0.36 0.24 0.16 - 0.11 0.01 0.34 0.14 0.30 0.33 0.91 
P-value 
 
0.329 0.551 0.627 0.69 0.007 0.743 0.932 0.558 0.711 0.586 0.565 0.341 
Total:                 
Cases (S/L) 
 
273/301 409/419 765/713 569/527 77/83 129/115 376/360 281/273 196/218 280/304 389/353 288/254 
Controls (S/L) 
 
2701/3031 2701/3031 2701/3031 2701/3031 1528/1736 1528/1736 1528/1736 1528/1736 1173/1295 1173/1295 1173/1295 1173/1295 
Heterogeneity: 
   
  
    Q (df = 2) 
 
2.27 1.81 0.40 0.37 5.78 1.20 0.38 1.41 0.29 0.50 0.11 0.03 
P-value 
 
0.322 0.405 0.819 0.831 0.055 0.550 0.825 0.495 0.865 0.781 0.945 0.984 
Cochran-Mantel-Haenszel Metaanalysis: 
   
  
    Fixed effect 
 
1.00 1.07 1.18 1.17 1.05 1.26 1.17 1.15 0.96 0.99 1.19 1.19 
P-value 
 
0.992 0.366 0.006 0.024 0.841 0.090 0.062 0.160 0.775 0.975 0.045 0.082 
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Table IV:  Association results of NOS1 ex1f-VNTR with comorbid co-morbid axis 2 and somatic disorders (Personality Disorder Cluster A (CL_A), B (CL_B) and 
C (CL_C), Migraine (Migr)) in the German, Norwegian and Spanish sample, followed meta-analysis. Along allele and genotype counts for cases and controls, the 
χ2- and the p-value of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender specific subsets are shown. Further, total 
cases and control allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model are given. Bold face indicates significant p-
values (p<0.05). 
  Total Females Males 
  CL_A CL_B CL_C Migr CL_A CL_B CL_C Migr CL_A CL_B CL_C Migr 
German Sample                 
Cases (S/L) 7/5 101/97 23/25 161/147 0/2 44/50 11/15 103/83 7/3 57/47 12/10 58/64 
Controls (S/L) 1870/2168 1870/2168 1870/2168 1870/2168 1162/1342 1162/1342 1162/1342 1162/1342 708/826 708/826 708/826 708/826 
χ2-value 0.70 1.68 0.05 4.09 - 0.01 0.17 5.59 - 2.93 0.61 0.09 
P-value 0.404 0.196 0.824 0.043 0.502 0.939 0.677 0.018 0.202 0.087 0.433 0.767 
Norwegian Sample                 
Cases (S/L) - - - 115/109 - - - 64/68 - - - 51/41 
Controls (S/L) - - - 519/551 - - - 283/309 - - - 236/242 
χ2-value - - - 0.60 - - - 0.02 - - - 1.13 
P-value - - - 0.440 - - - 0.887 - - - 0.287 
Spanish Sample                 
Cases (S/L) 2/4 25/29 16/8 43/23 - 2/6 4/2 21/11 2/4 23/23 12/6 22/12 
Controls (S/L) 312/312 312/312 312/312 312/312 83/85 83/85 83/85 83/85 229/227 229/227 229/227 229/227 
χ2-value - 0.27 2.57 5.49 - - - 2.83 - 0.00 1.87 2.66 
P-value 0.686 0.602 0.109 0.019 1.000 0.280 0.682 0.092 0.686 0.977 0.171 0.103 
Total:                 
Cases (S/L) 9/9 126/126 39/33 319/279 0/2 44/50 11/15 188/162 9/7 80/70 24/16 131/117 
Controls (S/L) 2701/3031 2701/3031 2701/3031 2701/3031 1528/1736 1528/1736 1528/1736 1528/1736 1173/1295 1173/1295 1173/1295 1173/1295 
Heterogeneity: 
   
  
    Q (df = 2) 1.26 1.11 1.42 2.77 0.53 1.62 0.84 2.92 2.37 0.93 0.32 1.77 
P-value 0.261 0.292 0.233 0.250 0.769 0.443 0.658 0.232 0.306 0.627 0.850 0.413 
Cochran-Mantel-Haenszel Metaanalysis: 
   
  
    Fixed effect 1.10 1.13 1.30 1.27 0.53 0.94 0.99  1.31 1.41 1.27 1.63 1.22 
P-value 0.980 0.397 0.327 0.007 0.544 0.840 0.874  0.022 0.662 0.184 0.182 0.165 
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